Drugplain

cholestyramine powder for suspension 4 g/8.78g

cholestyramine powder for suspension · POWDER, FOR SUSPENSION · Ascend Laboratories, LLC

No Recall History
Plain English

cholestyramine powder for suspension is a powder, for suspension containing cholestyramine powder for suspension at 4 g/8.78g, taken oral. Manufactured by Ascend Laboratories, LLC.

Key Facts

Brand Name
cholestyramine powder for suspension
Generic Name
cholestyramine powder for suspension
NDC Code (Product)
67877-298
Manufacturer
Ascend Laboratories, LLC
Strength
4 g/8.78g
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Marketing Status
Application #
ANDA211856
Drug Class
Bile Acid Sequestrant [EPC]
Marketing Start
10/20/2021

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

diarrhoea2 reports
therapy cessation2 reports
abdominal pain upper1 reports
cough1 reports
insomnia1 reports
loose tooth1 reports
nonspecific reaction1 reports
pain in jaw1 reports
product preparation issue1 reports
product quality issue1 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, ne

Dosage & Administration

DOSAGE AND ADMINISTRATION The recommended starting adult dose for cholestyramine for oral suspension, USP powder is 1 pouch or 1 level scoopful (8.780 grams of cholestyramine for oral suspension, USP powder contains 4 grams of anhydrous cholestyramine resin) once or twice a day. The recommended maintenance dose for cholestyramine for oral suspension, USP powder is 2 to 4 pouches or scoopfuls daily (8 to 16 grams anhydrous cholestyramine resin) divided into two doses. It is recommended that increases in dose be gradual with periodic assessment of lipid/lipoprotein levels at intervals of not less than 4 weeks. The maximum recommended daily dose is 6 pouches or scoopfuls of cholestyramine for oral suspension, USP powder (24 grams of anhydrous cholestyramine resin). The suggested time of administration is at mealtime but may be modified to avoid interference with absorption of other medications. Although the recommended dosing schedule is twice daily, cholestyramine for oral suspension, USP powder may be administered in 1 to 6 doses per day. Cholestyramine for Oral Suspension, USP powder should not be taken in its dry form. Always mix the dry powder with water or other fluids before in

Contraindications

CONTRAINDICATIONS Cholestyramine for oral suspension, USP powder is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components.

Drug Interactions

Drug Interactions Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins and digitalis. Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant. Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation. The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level while the patient was taking cholestyramine resin. Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E and K. When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered. SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS G

Adverse Reactions

ADVERSE REACTIONS The most common adverse reaction is constipation. When used as a cholesterol-lowering agent predisposing factors for most complaints of constipation are high dose and increased age (more than 60 years old). Most instances of constipation are mild, transient and controlled with conventional therapy. Some patients require a temporary decrease in dosage or discontinuation of therapy. Less Frequent Adverse Reactions- Abdominal discomfort and/or pain, flatulence, nausea, vomiting, diarrhea, eructation, anorexia, steatorrhea, bleeding tendencies due to hypoprothrombinemia (Vitamin K deficiency) as well as Vitamin A (one case of night blindness reported) and D deficiencies, hyperchloremic acidosis in children, osteoporosis, rash and irritation of the skin, tongue and perianal area. Rare reports of intestinal obstruction, including two deaths, have been reported in pediatric patients. Occasional calcified material has been observed in the biliary tree, including calcification of the gallbladder, in patients to whom cholestyramine resin has been given. However, this may be a manifestation of the liver disease and not drug related. One patient experienced biliary colic on e

Frequently Asked Questions

What is cholestyramine powder for suspension used for?

cholestyramine powder for suspension contains cholestyramine powder for suspension. It is a powder, for suspension taken oral. Consult your doctor for specific uses.

Is cholestyramine powder for suspension a controlled substance?

cholestyramine powder for suspension is not classified as a controlled substance by the DEA.

What is the generic name for cholestyramine powder for suspension?

The generic name for cholestyramine powder for suspension is cholestyramine powder for suspension. There are no other listed brand versions of cholestyramine powder for suspension.

What is the NDC code for cholestyramine powder for suspension 4 g/8.78g?

The NDC (National Drug Code) for cholestyramine powder for suspension 4 g/8.78g is 67877-298, listed by Ascend Laboratories, LLC.

Product NDC

67877-298

Package NDC

67877-298-37

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)